Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Founding Intercept CEO Pruzanski prepares to hand over the reins 

By Jeff Cranmer, Executive Editor
December 11, 2020 2:16 AM UTC

For the first time in its nearly 20-year history, Intercept will ring in the New Year with a new face in the corner office.

After guiding Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) through its launch in the years immediately after the bursting of the genomics bubble to an $86 million IPO in 2012 and the approval of its first marketed product in Ocaliva obeticholic acid, President and CEO Mark Pruzanski is handing over the reins to his COO, Jerry Durso. Pruzanski will become an adviser to the company and remain on its board...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Intercept Pharmaceuticals Inc.